PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11
Biotechnology company PYC Therapeutics Ltd (ASX:PYC) has begun a follow-up study in…
Pyc Therapeutics Limited (ASX:PYC)
About Pyc Therapeutics Limited
Key Information
PYC In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 23/07/2024 | Price Sensitive PS Extension of RP11 Single Dose Study Into Multiple Dose Study | 336.36KB | 1.9K |
| 22/07/2024 | Price Sensitive PS Quarterly Activities/Appendix 4C Cash Flow Report | 534.97KB | 385 |
| 17/07/2024 | Price Sensitive PS Initial Dosing Completed in Cohort 1 of RP11 MAD Study | 382.77KB | 4.1K |
| 12/07/2024 | Bioshares Biotech Summit Presentation | 1.16MB | 940 |
| 10/07/2024 | Price Sensitive PS Commencement of RP11 Multiple Dose Trial | 397.55KB | 19K |
| 02/07/2024 | Notification regarding unquoted securities - PYC | 17.61KB | 531 |
| 01/07/2024 | Price Sensitive PS RP11 Drug Candidate Safe and Well Tolerated | 240.23KB | 2.9K |
| 07/06/2024 | Price Sensitive PS PMS Drug Candidate Effective In Human Brain Cells | 297.34KB | 10K |